WEST HAVEN, Conn.--(BUSINESS WIRE)--Oct. 31, 2005--NanoViricides, Inc. (Pink Sheets:NNVC), today announced that it has commenced preclinical studies for its anti-viral drug FluCide-I(TM). The studies are being conducted at the Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School, under the direction of Dr. Krishna Menon. Dr. Menon, the Company's Chief Regulatory Officer, explained that nanoviricides are complex materials. "We have started working on the basic safety of the polymer under a maximum tolerated dose protocol in mice. In the second part we will study the ligands that target FluCide-I(TM) to H5N1 and common influenza viruses. Thereafter, we will study the efficacy of FluCide-I(TM) itself against H5N1 and common influenza."
Dr. Anil Diwan, President, explained that, "if successful, the relevance of nanoviricides can be compared to the discovery of Penicillin, the very first bactericide. Prior to antibiotics, bacterial infections were treated with patient isolation, chicken soup and Vitamin C. Current anti-viral medicines can at best only partially inhibit the virus from multiplying in the human body. Although we cannot make claims of certainty yet, after we get good results from these studies we will be able to say that we have developed a true virus killer."
The Company is encouraged by the recent statements from high level international officials and health ministers of different countries concerning the urgency of developing effective vaccines and treatments and believes that a rapid regulatory approval of FluCide-I(TM), is possible should these studies be successful.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A NanoViricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
Leo Ehrlich, 917-853-6440